Chemomab Therapeutics Ltd.
nebokitug
primary sclerosing cholangitis (PSC)
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for nebokitug in primary sclerosing cholangitis (PSC) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“On May 30, 2026, Chemomab will present data from three abstracts at EASL 2026, the Annual Congress of the European Association for the Study of the Liver in Barcelona, Spain.”